Fidelity Investments
LTRN icon

Fidelity Investments’s Lantern Pharma LTRN Stock Holding History

Fidelity Investments’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$685 Buy
+500
New +$1.4K ﹤0.01% 5131
2025
Q3 		– Sell
-74
Closed -$234 – 5499
2025
Q2 		$234 Buy
+74
New +$250 ﹤0.01% 5087
2024
Q3 		– Sell
-530
Closed -$2.47K – 5640
2024
Q2 		$2.47K Buy
+530
New +$3.19K ﹤0.01% 4690
2021
Q3 		– Sell
-1
Closed – – 4748
2021
Q2 		$0 Buy
+1
New +$15 ﹤0.01% 4618

Other funds holding LTRN

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments's LTRN Position: Q1 2026 in Review

Fidelity Investments opened a new position in Lantern Pharma (LTRN) in Q1 2026: 500 shares worth $685. The stake represents ﹤0.01% of the portfolio and ranks #5131 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in LTRN as recently as Q2 2025.

Fidelity Investments first reported a position in LTRN in Q2 2021 and has held it in 4 quarters since. The position peaked at $2.47K in Q2 2024. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

  • Fidelity Investments held 500 shares of Lantern Pharma worth $685 as of Q1 2026.
  • Lantern Pharma was a new Fidelity Investments position in Q1 2026.
  • Lantern Pharma made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #5131 holding.
  • Fidelity Investments first reported a position in Lantern Pharma in Q2 2021 and has held it in 4 quarters since.
  • Fidelity Investments's Lantern Pharma position peaked at $2.47K in Q2 2024.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.